Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors
Summary The prognosis of angiosarcoma remains very poor, even with combined, multimodal therapy. We report a case with partial response of angiosarcoma of the scalp to sorafenib, which is a new oral, molecular, targeted, multiple‐kinase inhibitor. In addition, we confirmed, using immunohistochemistr...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental dermatology 2012-10, Vol.37 (7), p.749-752 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 752 |
|---|---|
| container_issue | 7 |
| container_start_page | 749 |
| container_title | Clinical and experimental dermatology |
| container_volume | 37 |
| creator | Tamiya, H. Kamo, R. Kumei, A. Yanagihara, S. Ishii, M. Kobayashi, H. |
| description | Summary
The prognosis of angiosarcoma remains very poor, even with combined, multimodal therapy. We report a case with partial response of angiosarcoma of the scalp to sorafenib, which is a new oral, molecular, targeted, multiple‐kinase inhibitor. In addition, we confirmed, using immunohistochemistry, that sorafenib suppressed the expression of vascular endothelial growth factors and their receptors on the angiosarcoma tumour cells, and decreased cell numbers by inhibiting cellular proliferation. |
| doi_str_mv | 10.1111/j.1365-2230.2011.04316.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1074763116</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3376727631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4166-22caae4d8b1490c10f7b7995672afc6a4fd95998947bdf475a8d3042bf34222f3</originalsourceid><addsrcrecordid>eNpdkttu1DAQhiMEokvhFZAlhMTNBp9iJ0hclKUUpAoqxOnOmjh26yUbBztht-_Cw2KzyyLhG3s83_wzHk9RIIJLktbzdUmYqJaUMlxSTEiJOSOi3N0pFkfH3WKBGZZL0bD6pHgQ4xpjwois7hcnyS-aZCyKX1cQJgc9CiaOfogGeYtguHY-QtB-A9mebgyKGvoRTR5FH8CawbUvEMTotYPJ-QFt3XSDOqODgWg6ZHZjUozZkwR-QtRzDwGZofNJrc8Zr4PfphgLevIhpqRdTuRCKkWbMd89LO5Z6KN5dNhPi89vzj-t3i4vP1y8W51dLjUnQqTXagDDu7olvMGaYCtb2TSVkBSsFsBt11RNUzdctp3lsoK6Y5jT1jJOKbXstHi21x2D_zGbOKmNi9r0PQzGz1ERLLkUjBCR0Cf_oWs_hyFVp0jFq5rVlNSJenyg5nZjOjUGt4Fwq_72PQFPDwDkxtoAg3bxHye4wITLxL3cc1vXm9ujn2CV50CtVf7uLItVngP1Zw7UTq3OX-dTil_u412czO4YD-G7EpLJSn19f6E-0ldX376QWgn2G83DtvE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1545838218</pqid></control><display><type>article</type><title>Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Tamiya, H. ; Kamo, R. ; Kumei, A. ; Yanagihara, S. ; Ishii, M. ; Kobayashi, H.</creator><creatorcontrib>Tamiya, H. ; Kamo, R. ; Kumei, A. ; Yanagihara, S. ; Ishii, M. ; Kobayashi, H.</creatorcontrib><description>Summary
The prognosis of angiosarcoma remains very poor, even with combined, multimodal therapy. We report a case with partial response of angiosarcoma of the scalp to sorafenib, which is a new oral, molecular, targeted, multiple‐kinase inhibitor. In addition, we confirmed, using immunohistochemistry, that sorafenib suppressed the expression of vascular endothelial growth factors and their receptors on the angiosarcoma tumour cells, and decreased cell numbers by inhibiting cellular proliferation.</description><identifier>ISSN: 0307-6938</identifier><identifier>EISSN: 1365-2230</identifier><identifier>DOI: 10.1111/j.1365-2230.2011.04316.x</identifier><identifier>PMID: 22369131</identifier><identifier>CODEN: CEDEDE</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Dermatology ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - metabolism ; Hemangiosarcoma - drug therapy ; Hemangiosarcoma - metabolism ; Humans ; Male ; Medical research ; Medical sciences ; Middle Aged ; Niacinamide - analogs & derivatives ; Niacinamide - therapeutic use ; Phenylurea Compounds - therapeutic use ; Protein Kinase Inhibitors - therapeutic use ; Receptors, Vascular Endothelial Growth Factor - metabolism ; Scalp ; Skin Neoplasms - drug therapy ; Skin Neoplasms - metabolism ; Treatment Outcome ; Vascular Endothelial Growth Factors - metabolism</subject><ispartof>Clinical and experimental dermatology, 2012-10, Vol.37 (7), p.749-752</ispartof><rights>The Author(s). CED © 2012 British Association of Dermatologists</rights><rights>2015 INIST-CNRS</rights><rights>The Author(s). CED © 2012 British Association of Dermatologists.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4166-22caae4d8b1490c10f7b7995672afc6a4fd95998947bdf475a8d3042bf34222f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26460147$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22369131$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tamiya, H.</creatorcontrib><creatorcontrib>Kamo, R.</creatorcontrib><creatorcontrib>Kumei, A.</creatorcontrib><creatorcontrib>Yanagihara, S.</creatorcontrib><creatorcontrib>Ishii, M.</creatorcontrib><creatorcontrib>Kobayashi, H.</creatorcontrib><title>Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors</title><title>Clinical and experimental dermatology</title><addtitle>Clin Exp Dermatol</addtitle><description>Summary
The prognosis of angiosarcoma remains very poor, even with combined, multimodal therapy. We report a case with partial response of angiosarcoma of the scalp to sorafenib, which is a new oral, molecular, targeted, multiple‐kinase inhibitor. In addition, we confirmed, using immunohistochemistry, that sorafenib suppressed the expression of vascular endothelial growth factors and their receptors on the angiosarcoma tumour cells, and decreased cell numbers by inhibiting cellular proliferation.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Dermatology</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - metabolism</subject><subject>Hemangiosarcoma - drug therapy</subject><subject>Hemangiosarcoma - metabolism</subject><subject>Humans</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Niacinamide - therapeutic use</subject><subject>Phenylurea Compounds - therapeutic use</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Receptors, Vascular Endothelial Growth Factor - metabolism</subject><subject>Scalp</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Skin Neoplasms - metabolism</subject><subject>Treatment Outcome</subject><subject>Vascular Endothelial Growth Factors - metabolism</subject><issn>0307-6938</issn><issn>1365-2230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkttu1DAQhiMEokvhFZAlhMTNBp9iJ0hclKUUpAoqxOnOmjh26yUbBztht-_Cw2KzyyLhG3s83_wzHk9RIIJLktbzdUmYqJaUMlxSTEiJOSOi3N0pFkfH3WKBGZZL0bD6pHgQ4xpjwois7hcnyS-aZCyKX1cQJgc9CiaOfogGeYtguHY-QtB-A9mebgyKGvoRTR5FH8CawbUvEMTotYPJ-QFt3XSDOqODgWg6ZHZjUozZkwR-QtRzDwGZofNJrc8Zr4PfphgLevIhpqRdTuRCKkWbMd89LO5Z6KN5dNhPi89vzj-t3i4vP1y8W51dLjUnQqTXagDDu7olvMGaYCtb2TSVkBSsFsBt11RNUzdctp3lsoK6Y5jT1jJOKbXstHi21x2D_zGbOKmNi9r0PQzGz1ERLLkUjBCR0Cf_oWs_hyFVp0jFq5rVlNSJenyg5nZjOjUGt4Fwq_72PQFPDwDkxtoAg3bxHye4wITLxL3cc1vXm9ujn2CV50CtVf7uLItVngP1Zw7UTq3OX-dTil_u412czO4YD-G7EpLJSn19f6E-0ldX376QWgn2G83DtvE</recordid><startdate>201210</startdate><enddate>201210</enddate><creator>Tamiya, H.</creator><creator>Kamo, R.</creator><creator>Kumei, A.</creator><creator>Yanagihara, S.</creator><creator>Ishii, M.</creator><creator>Kobayashi, H.</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201210</creationdate><title>Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors</title><author>Tamiya, H. ; Kamo, R. ; Kumei, A. ; Yanagihara, S. ; Ishii, M. ; Kobayashi, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4166-22caae4d8b1490c10f7b7995672afc6a4fd95998947bdf475a8d3042bf34222f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Dermatology</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - metabolism</topic><topic>Hemangiosarcoma - drug therapy</topic><topic>Hemangiosarcoma - metabolism</topic><topic>Humans</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Niacinamide - therapeutic use</topic><topic>Phenylurea Compounds - therapeutic use</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Receptors, Vascular Endothelial Growth Factor - metabolism</topic><topic>Scalp</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Skin Neoplasms - metabolism</topic><topic>Treatment Outcome</topic><topic>Vascular Endothelial Growth Factors - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tamiya, H.</creatorcontrib><creatorcontrib>Kamo, R.</creatorcontrib><creatorcontrib>Kumei, A.</creatorcontrib><creatorcontrib>Yanagihara, S.</creatorcontrib><creatorcontrib>Ishii, M.</creatorcontrib><creatorcontrib>Kobayashi, H.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tamiya, H.</au><au>Kamo, R.</au><au>Kumei, A.</au><au>Yanagihara, S.</au><au>Ishii, M.</au><au>Kobayashi, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors</atitle><jtitle>Clinical and experimental dermatology</jtitle><addtitle>Clin Exp Dermatol</addtitle><date>2012-10</date><risdate>2012</risdate><volume>37</volume><issue>7</issue><spage>749</spage><epage>752</epage><pages>749-752</pages><issn>0307-6938</issn><eissn>1365-2230</eissn><coden>CEDEDE</coden><abstract>Summary
The prognosis of angiosarcoma remains very poor, even with combined, multimodal therapy. We report a case with partial response of angiosarcoma of the scalp to sorafenib, which is a new oral, molecular, targeted, multiple‐kinase inhibitor. In addition, we confirmed, using immunohistochemistry, that sorafenib suppressed the expression of vascular endothelial growth factors and their receptors on the angiosarcoma tumour cells, and decreased cell numbers by inhibiting cellular proliferation.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22369131</pmid><doi>10.1111/j.1365-2230.2011.04316.x</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0307-6938 |
| ispartof | Clinical and experimental dermatology, 2012-10, Vol.37 (7), p.749-752 |
| issn | 0307-6938 1365-2230 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1074763116 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Antineoplastic Agents - therapeutic use Biological and medical sciences Dermatology Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - metabolism Hemangiosarcoma - drug therapy Hemangiosarcoma - metabolism Humans Male Medical research Medical sciences Middle Aged Niacinamide - analogs & derivatives Niacinamide - therapeutic use Phenylurea Compounds - therapeutic use Protein Kinase Inhibitors - therapeutic use Receptors, Vascular Endothelial Growth Factor - metabolism Scalp Skin Neoplasms - drug therapy Skin Neoplasms - metabolism Treatment Outcome Vascular Endothelial Growth Factors - metabolism |
| title | Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T12%3A29%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Partial%20response%20of%20angiosarcoma%20of%20the%20scalp%20to%20sorafenib:%20association%20with%20decreased%20expression%20of%20vascular%20endothelial%20growth%20factors%20and%20their%20receptors&rft.jtitle=Clinical%20and%20experimental%20dermatology&rft.au=Tamiya,%20H.&rft.date=2012-10&rft.volume=37&rft.issue=7&rft.spage=749&rft.epage=752&rft.pages=749-752&rft.issn=0307-6938&rft.eissn=1365-2230&rft.coden=CEDEDE&rft_id=info:doi/10.1111/j.1365-2230.2011.04316.x&rft_dat=%3Cproquest_pubme%3E3376727631%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1545838218&rft_id=info:pmid/22369131&rfr_iscdi=true |